Every Form 4 that Tarsus Pharmaceuticals, Inc. (TARS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TARS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TARS filings page.
PYOTT DAVID E I reported acquisition or exercise transactions in this Form 4 filing.
Tarsus Pharmaceuticals director David E. I. Pyott received new equity awards. On February 18, 2026, he was granted 5,893 stock options with a right to buy Tarsus common stock and 3,729 restricted stock units (RSUs).
The option grant will vest in three equal annual installments on February 18 of 2027, 2028, and 2029, contingent on his continuous service. Each RSU represents one share of common stock and will vest in three equal annual installments on March 15 of 2027, 2028, and 2029, also subject to continued service.
Tarsus Pharmaceuticals, Inc. director Katherine Goodrich reported the settlement of vested restricted stock units into common shares. On December 15, 2025, 2,233 restricted stock units (RSUs) were converted into 2,233 shares of common stock at a reported price of $0.00 per share, which she now holds directly.
Following this transaction, Goodrich directly holds 2,233 common shares and 4,467 RSUs. The RSUs are scheduled to vest in three equal installments on December 15 of 2025, 2026 and 2027, subject to her continuous service with the company, with each RSU representing the right to receive one share of Tarsus common stock.
Tarsus Pharmaceuticals’ Chief Human Resources Officer, Dianne C. Whitfield, reported automatic stock sales made under a pre-arranged Rule 10b5-1 trading plan. On January 2, 2026, she sold a total of 15,565 shares of Tarsus common stock in four transactions at weighted average prices ranging from about $80.09 to $82.93. The footnotes explain that each reported price is a weighted average for multiple individual trades, with actual prices spanning from $79.42 to $83.32. After these sales, she directly owned 23,393 shares of Tarsus common stock.
Tarsus Pharmaceuticals, Inc. Chief Operating Officer reported stock gifts in an insider filing. On 12/16/2025, he transferred 950 shares of common stock at a stated price of $0, leaving 79,183 shares of common stock held directly, which includes 451 shares acquired under the company’s Employee Stock Purchase Plan on June 30, 2025.
A separate reported transaction on the same date reflects a gift coded as G(2) involving 475 shares of common stock held indirectly by his daughter. The report notes that he disclaims beneficial ownership of the securities held by his daughter and that this reporting is not an admission of beneficial ownership for Section 16 or any other purpose.
Tarsus Pharmaceuticals, Inc. disclosed that its Chief Human Resources Officer, an officer of the company, sold common stock in a pre‑planned trade. On 12/16/2025, the officer sold 7,397 shares of Tarsus common stock at a price of $80.1 per share in a transaction coded as a sale. The filing states that this was an automatic sale made under a Rule 10b5‑1 trading plan adopted on September 12, 2025, indicating the trade was scheduled in advance. After this transaction, the officer beneficially owned 38,958 shares of Tarsus common stock, held directly.
Tarsus Pharmaceuticals, Inc. reported insider stock sales by a company director. On December 15, 2025, the reporting person sold several blocks of Tarsus common stock in open-market transactions. Direct holdings were reduced through sales of 5,046 shares at a weighted average price of $80.8, 6,306 shares at $81.75, and 1,148 shares at $82.39, among other trades.
Some of these sales were executed automatically under a Rule 10b5-1 trading plan adopted on September 8, 2025, while others were not made under such a plan. The director also sold shares held indirectly through Link Family Enterprise, LP. After the reported transactions, the reporting person directly owned 128,832 Tarsus shares and no longer held shares indirectly through the partnership.
Tarsus Pharmaceuticals, Inc. Chief Medical Officer reported equity transactions tied to restricted stock units (RSUs). On December 15, 2025, 6,819 RSUs vested and were settled into an equal number of common shares. On December 16, 2025, 2,078 common shares were sold at $79.5 per share to cover tax withholding obligations under a mandated “sell to cover” arrangement, rather than as a discretionary sale.
After these transactions, the officer beneficially owned 24,019 common shares directly, plus 6,360 shares held indirectly through a spouse’s Roth IRA and 12,040 shares held through a 401(k) plan. The officer also held 20,459 RSUs, which each represent a contingent right to receive one share of common stock and vest in four equal annual installments on December 15 of 2025, 2026, 2027, and 2028, subject to continuous service.
Tarsus Pharmaceuticals President and CEO Bobak Azamian, who is also Board Chair and a director, reported a transfer of 51,885 shares of common stock on December 4, 2025. The shares were moved for no consideration to the Bobak Azamian Living Trust, established April 16, 2018.
After the transaction, he holds 1,750 Tarsus shares directly and 863,991 shares indirectly through the trust, where he serves as trustee with voting and dispositive power over these shares. The report reflects a restructuring of how his holdings are owned rather than a cash sale.